Schering-Plough

(SGP)

is in trouble with the government again. This time the

U.S. Attorney's Office

in Massachusetts is looking into the company's pricing tactics.

The drugmaker, which is based in Madison, N.J., said in its annual report, filed with the

Securities and Exchange Commission

, that the U.S. Attorney's office is examining whether the wholesale price of drugs as set by the company is inappropriately higher than the average price paid by distributors. It also said the investigation is exploring the possibility that the company broke the law by inflating prices on drugs that are reimbursable by the government.

The company is also under the looking glass for possible violations stemming from the prices charged on repackaged products by a managed care organization.

Shares of Schering-Plough fell 53 cents, or 1.4%, to $37.52 in regular session

New York Stock Exchange

trading.

Schering-Plough said in

mid-February that the

Food and Drug Administration

was looking into "deficiencies concerning compliance with current good manufacturing practices" at two of its plants in New Jersey and one in Puerto Rico. The plants under investigation are major suppliers of the company's products in the U.S., including the antihistamine Claritin.